Literature DB >> 22919477

Acid-fast bacilli other than mycobacteria in tuberculosis patients receiving directly observed therapy short course in cross river state, Nigeria.

Benjamin Thumamo Pokam1, Anne E Asuquo.   

Abstract

The information on the contribution of non tuberculous mycobacteria (NTM) to mycobacterial infections in Africa is scarce due to limited laboratory culture for its isolation and identification. One hundred and thirty-seven sputum smear positive patients were recruited into a study on the molecular epidemiology of Mycobacterium tuberculosis in Cross River State. Following sputum culture, 97 pure isolates were obtained and identified using Capilia TB-Neo and further confirmed by the GenoType Mycobacterium CM kit. Of the 97 isolates, 81 (83.5%) isolates were Capilia TB-Neo positive while 16 (16.5%) were Capilia TB-Neo negative. Further confirmation with the GenoType Mycobacterium CM kit revealed that 4 (25%) of the 16 isolates belonged to NTM and included M. fortuitum I, M. fortuitum II/M magaritense, M. abscessus, and M. avium ssp. The remaining 12 (75%) Capilia TB-Neo negative isolates were not members of the genus Mycobacterium despite their AFB appearance. Six (33.3%) of the Capilia TB-Neo negative were from HIV positive tuberculosis patients. All subjects in this study were placed on DOTS shortly after the AFB results were obtained. The implication of isolation of 16.5% nontuberculous isolates further emphasizes the need for culture of sputum specimen especially in HIV positive patients prior to administration of antituberculosis therapy.

Entities:  

Year:  2012        PMID: 22919477      PMCID: PMC3413975          DOI: 10.1155/2012/301056

Source DB:  PubMed          Journal:  Tuberc Res Treat        ISSN: 2090-150X


1. Introduction

Mycobacterium tuberculosis is the most important causative agent of tuberculosis (TB) while nontuberculous mycobacteria (NTM) may play a key role in etiology of TB-like syndromes [1]. Data on nontuberculous mycobacterial disease in sub-Saharan Africa are limited, due mainly to the lack of laboratory culture facilities for the identification of mycobacterial species. Consequently, many laboratories do not discriminate between M. tuberculosis and NTM for similar reasons [2-4]. Treatment of TB patients in most sub-Saharan African countries including Nigeria is based solely on the results of microscopic smear positivity. As such, all sputum smear positive diagnosed patients are indiscriminately placed on DOTS, the current international TB treatment strategy. The implication is that NTM is inappropriately managed with first-line antituberculous drug [4, 5], worsening the patient's condition and raising the risk of drug resistance. Although it is known that most sputum smear positive patients are truly TB patients [6], the continued increase in TB drug resistance raises the question on the impact of this indiscriminate use of TB drugs to treat all diagnosed sputum smear positive patients. In assessing the molecular epidemiology of Mycobacterium tuberculosis complex in the Cross River State of Nigeria, the data revealed the involvement of AFB other than mycobacteria in tuberculosis-like symptoms in the population.

2. Materials and Methods

2.1. Patients and Setting

The study was carried out in Cross River State, located in the South-South part of Nigeria. Patients included 137 smear positive patients from which 3 consecutive sputum specimens were collected. Patients were recruited over a period of 12 months (June 2008 to May 2009) from the major hospitals and TB care facilities in the north, central, and south senatorial districts of the state. Both genders and age groups of 10 to 70 years were included. Permission to carry out the work was obtained from the local ethical committee, and informed medical consent was equally obtained from all participating patients.

2.2. Sputum Cultures

Sputum specimen obtained from patients was preserved using sodium carbonate (75 mg) and/or refrigerated until cultured. Specimens were decontaminated using modified Petroff's method [7] and cultured using BACTEC 960 (Becton Dickinson, Franklin Lakes, NJ07417, USA). Smears were made from isolates obtained from the BACTEC MGIT tubes, stained by the Ziehl Neelsen staining method, and examined for the presence of acid-fast bacilli (AFB). The growth on AFB positive MGIT tubes was further inoculated into two Lowenstein-Jensen slants, one containing sodium pyruvate. The cultures were examined twice a week and their rate of growth and colonial morphologies recorded. Contaminated slants were further re-decontaminated and recultured. Negative cultures and discarded heavily contaminated slants reduced our working cultures to 97 pure isolates.

2.3. Identification of Isolates

Primary identification of organisms using Capilia TB-Neo (TAUNS Laboratories, Inc. Japan), an immunochromatographic method which can detect MPT64, a protein specifically secreted by M. tuberculosis complex and not produced by NTM, was performed according to the manufacturer's instructions (http://capilia.jp/english/capilia_tb_neo.html). To determine the species of the Capilia TB-Neo negative isolates, the GenoType Mycobacterium CM kit, a test based on the DNA-STRIP technology that permits the identification of some mycobacterial species, was used according to the manufacturer's instructions (Hain Lifescience GmbH, Nehren, Germany). Briefly, DNA extraction was carried out by sonication on the cultured organisms, heat killed at 80°C for 30 minutes, followed by a multiplex amplification with biotinylated primers and a reverse hybridization. The hybridization included the chemical denaturation of the amplification products, hybridization of a single-stranded, biotin-labeled amplicons to membrane-bound probes, stringent washing, addition of a streptavidin/alkaline phosphatase conjugate, and an alkaline phosphatase mediated staining reaction. A template ensured the easy and fast interpretation of the banding pattern obtained. Three controls (conjugate, universal, and genus) are included in each strip.

3. Results

Following culture and identification of the 97 isolates in this study, 81 (83.5%) were identified as members of the Mycobacterium tuberculosis complex (data published [8]) using both immunochromatographic technique (Capilia TB-Neo positive) and GenoType Mycobacterium CM. Eighteen (18.6%) patients were HIV positive. However, 21 individuals did not know their HIV status at the time the study was carried out. Of the 18 HIV positive TB patients, 6 (33.3%) were Capilia negative (P = 0.09) (Table 1).
Table 1

Association of mycobacteria genus and HIV status of subjects.

HIV status Capilia TB-Neo
Positive (%)Negative (%)Total
Positive12 (66.7)6 (33.3)18
Negative50 (86.2)8 (13.8)58
Unknown19 (90.5)2 (9.5)21

Total811697
Of the 16 Capilia negative isolates, GenoType Mycobacterium CM molecular test identified 4 isolates as M. fortuitum I, M. fortuitum II/M magaritense, M. abscessus, and M. avium ssp. Two of the 4 isolates were obtained from HIV positive patients. Twelve AFB smear positive isolates were found not to be members of the genus mycobacteria, as shown in Table 2.
Table 2

Genotype mycobacteria identification of Capilia TB-Neo negative isolates from sputum smear positive patients.

Isolates no.Sex/AgeStrainsHIV status
0015IDHF/25–34NMNEG
0033THF/25–34NMPOS
0043THM/35–44NMNEG
0053THM/35–44NMPOS
0073IDHM/45–54 M. fortuitum I POS
0082IDHM/25–34NMUNK
0083IDHF/25–34NMNEG
0086IDHF/25–34NMPOS
0089IDHM/25–34 M. fortuitum IINEG
/M. magaritense
0094IDHF/25–34NMNEG
0105THF/15–24NMNEG
00111IDHM/25–34NMPOS
00113IDHM/15–24NMNEG
00128THM/25–34NMNEG
00134THM/35–44 M. abcessus POS
00407OGF/35–44 M. avium ssp. UNK

F: female; M: male; NM: not member of the genus mycobacteria; POS: positive; NEG: negative; UNK: unknown.

4. Discussion

In recent times, several newer immunochromatographic techniques have emerged (e.g., Capilia) making rapid differentiation between M. tuberculosis complex and NTM possible and less cumbersome, even though they cannot identify the NTM species. Although it has been shown that most cultures-positive mycobacteria are M. tuberculosis in regions where tuberculosis is highly prevalent [6, 9], NTM isolates have been increasing gradually. Up to 20–30% of AFB smear positive isolates have been identified as NTM in Korea [10]. These organisms can cause true infection and disease and can be important clinically [11]. In Africa, the contribution of NTM to such disease has been examined on a small scale only [1]. Two previous studies in Nigeria show that Fawcett and Watkins [12] did not isolate mycobacteria other than those causing tuberculosis in their study in the northern region of the country. However, 11% atypical Mycobacteria have been reported in Lagos in 1986 [6]. The latter authors classified six as M. avium, four as M. kansasii, and one as M. fortuitum. The four NTM species isolated in this study included M. fortuitum I, M. fortuitum II/M. magaritense, and M. avium species besides M. abscessus. Two studies carried in the country have equally isolated M. fortuitum, M. intracellulare, M. chelonae, M. avium, and M. kansasi among sputum smear positive samples/culture isolates [9, 13]. Most NTM disease cases involve species of M. avium complex, M. abscessus, M. fortuitum, and M. kansasii. M. abscessus is being seen with increasing frequency and is particularly difficult to treat medically [14], because the disease caused by M. abscessus often progresses slowly over years and because older adults are typically affected. In more developed countries, M. avium and M. simiae are responsible for disseminated disease in HIV-infected persons [15]. The HIV era has brought an increase of infection by these opportunistic human pathogens. Nontuberculous mycobacteria are involved in a range of diseases including pulmonary disease, hypersensitivity pneumonitis, cervical lymphadenitis, and disseminated infection. The disseminated infection is generally associated with HIV infection: AIDS and immunosuppression [16]. Though this study did not show any association between the NTM and HIV infection, this could be attributed to the number of patients that did not know their status at the time of specimen collection. In 2008, when patients in this study were being sampled, HIV counseling and testing in Nigeria were not compulsory for TB suspects or patients newly diagnosed with TB. Moreover, in 2007, only 3 percent of health facilities in Nigeria had HIV testing and counseling services [17]. Of the initial 16 NTM isolated in this study, molecular techniques showed that 12 were not members of the genus Mycobacterium, despite the fact that they were isolated from sputum smear positive patients. It may be that these organisms are Nocardia species or Rhodococcus equi, since their microscopic appearance was consistent with AFB. The incidence of nocardiosis especially the former Nocardia asteroides complex has been on the increase due to the increase in the number of immunosuppressed patients during recent decades [18]. More than 70% of patients with nocardial infection are immunocompromised, and disseminated nocardiosis is associated with several immunocompromising conditions. More recently, HIV infection has been described as a risk factor for disseminated nocardiosis [19]. Pulmonary nocardiosis is very often misdiagnosed as tuberculosis and treated with antitubercular drugs. Such cases may end fatally [20].

5. Conclusion

The challenge therefore in most African countries, and especially in Nigeria, still remains the introduction in a large scale of laboratory culture for the specific identification of the mycobacteria. The data obtained in this study provide some evidence of the role of nontuberculous AFB organisms and the public health implications of DOTS administration without sputum culture. Sputum culture should be performed in smear positive patients with known HIV positive status or HIV patients with clinical symptoms of tuberculosis, so as to identify the strains involved and thus avoid unnecessary administration of anti-TB drugs with risk of drug toxicity for the patients and increase drug resistance. Half (2/4) of the patients in this study with the identified NTM were HIV positive. Moreover, drug resistance should not be systematically considered as it is currently the case, especially in patients still AFB smear positive following intensive phase treatment in settings devoid of culture facilities, as such patients may be either infected by NTM or AFB not members of the genus mycobacteria.
  11 in total

Review 1.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

Review 2.  Nocardiasis in patients with HIV infection.

Authors:  F Márquez-Diaz; L E Soto-Ramirez; J Sifuentes-Osornio
Journal:  AIDS Patient Care STDS       Date:  1998-11       Impact factor: 5.078

3.  Disseminated nocardiosis in an advanced AIDS patient.

Authors:  S V S Malladi; P K Ankathi; L Vemu; N M Rao
Journal:  J Assoc Physicians India       Date:  2010-05

4.  Molecular epidemiology and genetic diversity of Mycobacterium tuberculosis complex in the Cross River State, Nigeria.

Authors:  Benjamin P Thumamo; Anne E Asuquo; Lydia N Abia-Bassey; Lovett Lawson; Véronique Hill; Thierry Zozio; Nnamdi Emenyonu; Francis O Eko; Nalin Rastogi
Journal:  Infect Genet Evol       Date:  2011-08-22       Impact factor: 3.342

Review 5.  Nontuberculous mycobacterial infections: a clinical review.

Authors:  D Wagner; L S Young
Journal:  Infection       Date:  2004-10       Impact factor: 3.553

6.  Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients.

Authors:  D E Griffith; W M Girard; R J Wallace
Journal:  Am Rev Respir Dis       Date:  1993-05

7.  Human pulmonary infections with bovine and atypical mycobacteria in Lagos, Nigeria.

Authors:  E O Idigbe; C E Anyiwo; D I Onwujekwe
Journal:  J Trop Med Hyg       Date:  1986-06

8.  Initial resistance of Mycobacterium tuberculosis in Northern Nigeria.

Authors:  I W Fawcett; B J Watkins
Journal:  Tubercle       Date:  1976-03

9.  Human pulmonary infections with bovine and environment (atypical) mycobacteria in jos, Nigeria.

Authors:  Jd Mawak; Ne Gomwalk; Css Bello; Yt Kandakai-Olukemi
Journal:  Ghana Med J       Date:  2006

10.  Nontuberculous mycobacteria, zambia.

Authors:  Patricia C A M Buijtels; Marianne A B van-der-Sande; Cas S de-Graaff; Shelagh Parkinson; Henri A Verbrugh; Pieter L C Petit; Dick van-Soolingen
Journal:  Emerg Infect Dis       Date:  2009-02       Impact factor: 6.883

View more
  11 in total

1.  Non-tuberculous Mycobacteria isolated from Pulmonary samples in sub-Saharan Africa - A Systematic Review and Meta Analyses.

Authors:  Catherine Okoi; Suzanne T B Anderson; Martin Antonio; Sarah N Mulwa; Florian Gehre; Ifedayo M O Adetifa
Journal:  Sci Rep       Date:  2017-09-20       Impact factor: 4.379

2.  Prevalence of non-tuberculous mycobacteria among previously treated TB patients in the Gulf of Guinea, Africa.

Authors:  B D Thumamo Pokam; D Yeboah-Manu; S Ofori; P W Guemdjom; P M Teyim; L Lawson; D Amiteye; N Y Yhiler; I C Djuikoue; A E Asuquo
Journal:  IJID Reg       Date:  2022-05-14

3.  Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB.

Authors:  Anne F Luetkemeyer; Michelle A Kendall; Xingye Wu; Maria Cristina Lourenço; Ute Jentsch; Susan Swindells; Sarojini S Qasba; Jorge Sanchez; Diane V Havlir; Beatriz Grinsztejn; Ian M Sanne; Cynthia Firnhaber
Journal:  J Clin Microbiol       Date:  2014-01-15       Impact factor: 5.948

4.  Molecular Analysis of Mycobacterium tuberculosis Isolated in the North Central Zone of Nigeria.

Authors:  Benjamin David Thumamo Pokam; Dorothy Yeboah-Manu; Lovett Lawson; Prisca Wabo Guemdjom; Ruth Okonu; Laura Madukaji; Nchawa Yangkam Yhiler; Anne Ebri Asuquo
Journal:  J Epidemiol Glob Health       Date:  2019-12

5.  DNA Electrochemical Biosensor Based on Iron Oxide/Nanocellulose Crystalline Composite Modified Screen-Printed Carbon Electrode for Detection of Mycobacterium tuberculosis.

Authors:  Mohd Hazani Mat Zaid; Che Engku Noramalina Che-Engku-Chik; Nor Azah Yusof; Jaafar Abdullah; Siti Sarah Othman; Rahizan Issa; Mohd Fairulnizal Md Noh; Helmi Wasoh
Journal:  Molecules       Date:  2020-07-24       Impact factor: 4.411

6.  Prevalence of non-tuberculous mycobacterial infections among tuberculosis suspects in Nigeria.

Authors:  Gambo Aliyu; Samer S El-Kamary; Alash'le Abimiku; Clayton Brown; Kathleen Tracy; Laura Hungerford; William Blattner
Journal:  PLoS One       Date:  2013-05-09       Impact factor: 3.240

7.  Risk factors in patients with AFB smear-positive sputum who receive inappropriate antituberculous treatment.

Authors:  Cheng-Yu Chang; Jen-Yee Hong; Mei-Kang Yuan; Shu-Ju Chang; Yuan-Ming Lee; Shih-Chieh Chang; Li-Cho Hsu; Shin-Lung Cheng
Journal:  Drug Des Devel Ther       Date:  2013-01-31       Impact factor: 4.162

8.  Leveraging Advances in Tuberculosis Diagnosis and Treatment to Address Nontuberculous Mycobacterial Disease.

Authors:  Ravikiran M Raju; Sagar M Raju; Yanlin Zhao; Eric J Rubin
Journal:  Emerg Infect Dis       Date:  2016-03       Impact factor: 6.883

9.  Non-tuberculous mycobacteria (NTM) in Zambia: prevalence, clinical, radiological and microbiological characteristics.

Authors:  Pascalina Chanda-Kapata; Nathan Kapata; Eveline Klinkenberg; Lutinala Mulenga; Mathias Tembo; Patrick Katemangwe; Veronica Sunkutu; Peter Mwaba; Martin P Grobusch
Journal:  BMC Infect Dis       Date:  2015-11-06       Impact factor: 3.090

10.  Incidence, Clinical Manifestation, Treatment Outcome, and Drug Susceptibility Pattern of Nontuberculous Mycobacteria in HIV Patients in Tehran, Iran.

Authors:  Seifu Gizaw Feysia; Malihe Hasan-Nejad; Siroos Amini; Gholamreza Hamzelou; Hossein Kazemian; Jalil Kardan-Yamchi; Morteza Karami-Zarandi; Mohammad Mehdi Feizabadi
Journal:  Ethiop J Health Sci       Date:  2020-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.